Caladrius Biosciences, Inc. (CLBS)

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences' Second Quarter 2022 Financial Results and Business Update Conference Call. Currently all participants are in listen-only mode.

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.

NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: GTY Technology Holdings Inc. (NASDAQ: GTYH) 's  sale to GI Partners for $6.30 in cash per share. If you are a GTY Technology shareholder, click here to learn more about your rights and options.

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kristen Buck - Chief Medical Officer Conference Call Participants Kumar Raja - Brookline Capital Markets Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences First Quarter 2022 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.

Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of each company.  The transaction values each company at $90.

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript

BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms.

Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript

BASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2021 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of 33.33% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.